吉非替尼治疗58例晚期非小细胞肺癌的临床观察

目的:观察吉非替尼对晚期非小细胞肺癌的临床疗效及不良反应,以及对生活质量的影响。方法:选择2006年7月～2008年12月间ⅢB～Ⅳ期非小细胞肺癌患者58例,口服吉非替尼250 mg/次,每天一次,服药至病情进展或出现不能耐受的不良反应为止。结果:58例可评价非小细胞肺癌患者中,CR 1例(1.72%),PR 19例(32.76%),SD 24例(41.38%),PD 14例(24.14%),总有效率(RR)为34.48%,总的疾病控制率(DCR)为75.86%;腺癌的有效率高于鳞癌,女性的有效率高于男性,不吸烟者有效率高于吸烟者(P<0.05),接受过化疗和Ⅳ期患者有效率稍高,但无显著统计学差异(P>0.05)。中位生存时间11.3个月,1年生存率为43.6%,主要的不良反应中皮疹发生最多为39例(67.24%),腹泻14例(24.14%),肝功能轻度损害2例(3.45%)。结论:吉非替尼治疗晚期非小细胞肺癌疗效好,可以显著改善非小细胞肺癌患者的临床症状及生存质量,毒副反应较小,安全易耐受。

Clinical observation of gefitinib for 58 patients with advanced non-small cell lung cancer

Objective To observe the clinical efficacy,quality of life and toxic reaction of gefitinib in the treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods Fifty-eight patients with IIIB to IV NSCLC were selected from July 2006 to December 2008.The gefitinib was oral intake at 250 mg once a day until the disease progression or intolerable toxic reaction occurred.Results All 58 patients were evaluable for therapeutic effect.Among the 58 patients,1 cases got complete response(CR,1.72%).19 cases partial response(PR,32.76%),24 cases stable disease(SD,41.48%)and 14 cases progression(PD,24.14%).The total response rate(RR) was 34.48% and the disease control rate(DCR) was 75.86%,The response rate was significantly higher in females,adenocarcinoma and nonsmokers than in males,squamous carcinoma and smokers(P<0.05).The response rate was higher in previous treatment and Ⅳ stage,but that did not show significant differences in statistics(P>0.05).The one-year survival rate 43.4%.The median survival time was 11.3 months,The one-year surviva1 rate was 43.6%.The main toxicity of Gefitinib was skin rash,It were 39 cases(67.24%);14 cases diarrhoea(24.14%),the mildly harm of liver function were 2 cases(3.45%).Conclusion Gefitinib may obviously improve the clinical symptom and quality of life of the advanced NSCLC patient,it is better efficacy and safe,well-tolerated toxicity.